Searched for
GREVLIMID SALES TAPER
Dr Reddy’s Laboratories shares fall over 1% on Q2 results. Should you buy, sell or hold?Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...- Banking and IT show muted growth, pharma thrives in March quarter resultsMarch quarter results reveal mixed performance across sectors. Banking and IT experienced muted profit growth, while pharma demonstrated st...
- DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...
- Load More